Related references
Note: Only part of the references are listed.Obeticholic Acid Improves Adipose Morphometry and Inflammation and Reduces Steatosis in Dietary but not Metabolic Obesity in Mice
Fahrettin Haczeyni et al.
OBESITY (2017)
Farnesoid X receptor induces Takeda G-protein receptor 5 cross-talk to regulate bile acid synthesis and hepatic metabolism
Preeti Pathak et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2017)
The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction
Philipp Schwabl et al.
JOURNAL OF HEPATOLOGY (2017)
miR-21 ablation and obeticholic acid ameliorate nonalcoholic steatohepatitis in mice
Pedro M. Rodrigues et al.
CELL DEATH & DISEASE (2017)
Antifibrotic effect of pirfenidone in a mouse model of human nonalcoholic steatohepatitis
Chikara Komiya et al.
SCIENTIFIC REPORTS (2017)
Farnesoid X receptor activation protects the kidney from ischemia-reperfusion damage
Zhibo Gai et al.
SCIENTIFIC REPORTS (2017)
CD11c+ resident macrophages drive hepatocyte death-triggered liver fibrosis in a murine model of nonalcoholic steatohepatitis
Michiko Itoh et al.
JCI INSIGHT (2017)
Identification of Novel Noninvasive Markers for Diagnosing Nonalcoholic Steatohepatitis and Related Fibrosis by Data Mining
Keito Yoshimura et al.
HEPATOLOGY (2016)
A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
F. Nevens et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis
Len Verbeke et al.
SCIENTIFIC REPORTS (2016)
New paradigms in the treatment of hepatic cholestasis: From UDCA to FXR, PXR and beyond
Ulrich Beuers et al.
JOURNAL OF HEPATOLOGY (2015)
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
Brent A. Neuschwander-Tetri et al.
LANCET (2015)
D Farnesoid X Receptor Antagonizes JNK Signaling Pathway in Liver Carcinogenesis by Activating SOD3
Yan-Dong Wang et al.
MOLECULAR ENDOCRINOLOGY (2015)
Eicosapentaenoic Acid Ameliorates Non-Alcoholic Steatohepatitis in a Novel Mouse Model Using Melanocortin 4 Receptor-Deficient Mice
Kuniha Konuma et al.
PLOS ONE (2015)
Free Cholesterol Accumulation in Hepatic Stellate Cells: Mechanism of Liver Fibrosis Aggravation in Nonalcoholic Steatohepatitis in Mice
Kengo Tomita et al.
HEPATOLOGY (2014)
Obeticholic Acid, a Farnesoid X Receptor Agonist, Improves Portal Hypertension by Two Distinct Pathways in Cirrhotic Rats
Len Verbeke et al.
HEPATOLOGY (2014)
p53 regulates a non-apoptotic death induced by ROS
J. Montero et al.
CELL DEATH AND DIFFERENTIATION (2013)
Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
Sunder Mudaliar et al.
GASTROENTEROLOGY (2013)
Inhibition of p53 attenuates steatosis and liver injury in a mouse model of non-alcoholic fatty liver disease
Zoltan Derdak et al.
JOURNAL OF HEPATOLOGY (2013)
miR-34a/SIRT1/p53 is suppressed by ursodeoxycholic acid in the rat liver and activated by disease severity in human non-alcoholic fatty liver disease
Rui E. Castro et al.
JOURNAL OF HEPATOLOGY (2013)
Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome
Shin Yoshimoto et al.
NATURE (2013)
Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis
Quentin M. Anstee et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2013)
From NAFLD to NASH to cirrhosis - new insights into disease mechanisms
Alexander Wree et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2013)
Ageing Fxr Deficient Mice Develop Increased Energy Expenditure, Improved Glucose Control and Liver Damage Resembling NASH
Mikael Bjursell et al.
PLOS ONE (2013)
Hepatic Crown-Like Structure: A Unique Histological Feature in Non-Alcoholic Steatohepatitis in Mice and Humans
Michiko Itoh et al.
PLOS ONE (2013)
Disruption of phospholipid and bile acid homeostasis in mice with nonalcoholic steatohepatitis
Naoki Tanaka et al.
HEPATOLOGY (2012)
The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association
Naga Chalasani et al.
HEPATOLOGY (2012)
The epidemiology, pathogenesis and histopathology of fatty liver disease
Adam P. Levene et al.
HISTOPATHOLOGY (2012)
p53/p66Shc-mediated signaling contributes to the progression of non-alcoholic steatohepatitis in humans and mice
Kengo Tomita et al.
JOURNAL OF HEPATOLOGY (2012)
Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease
Geoffrey Porez et al.
JOURNAL OF LIPID RESEARCH (2012)
Cross-Regulation of Protein Stability by p53 and Nuclear Receptor SHP
Zhihong Yang et al.
PLOS ONE (2012)
Melanocortin 4 Receptor-Deficient Mice as a Novel Mouse Model of Nonalcoholic Steatohepatitis
Michiko Itoh et al.
AMERICAN JOURNAL OF PATHOLOGY (2011)
Generalizability of the Nonalcoholic Steatohepatitis Clinical Research Network Histologic Scoring System for Nonalcoholic Fatty Liver Disease
Ravi Juluri et al.
JOURNAL OF CLINICAL GASTROENTEROLOGY (2011)
Increases in p53 expression induce CTGF synthesis by mouse and human hepatocytes and result in liver fibrosis in mice
Takahiro Kodama et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats
Sabrina Cipriani et al.
JOURNAL OF LIPID RESEARCH (2010)
The C terminus of p53 binds the N-terminal domain of MDM2
Masha V. Poyurovsky et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2010)
Mitochondrial Glutathione, a Key Survival Antioxidant
Montserrat Mari et al.
ANTIOXIDANTS & REDOX SIGNALING (2009)
Apoptosis in experimental NASH is associated with p53 activation and TRAIL receptor expression
Geoffrey C. Farrell et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2009)
Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis
Songwen Zhang et al.
JOURNAL OF HEPATOLOGY (2009)
Acetylation is indispensable for p53 activation
Yi Tang et al.
CELL (2008)
Expression of p53, Bax and Bcl-2 proteins in hepatocytes in non-alcoholic fatty liver disease
Anatol Panasiuk et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2006)
Divergence of melanocortin pathways in the control of food intake and energy expenditure
N Balthasar et al.
CELL (2005)
A farnesoid X receptor-small heterodimer partner regulatory cascade modulates tissue metalloproteinase inhibitor-1 and matrix metalloprotease expression in hepatic stellate cells and promotes resolution of liver fibrosis
S Fiorucci et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2005)
Expression and activation of the farnesoid X receptor in the vasculature
D Bishop-Bailey et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis
S Fiorucci et al.
GASTROENTEROLOGY (2004)
Hepatocyte apoptosis and Fas expression are prominent features of human nonalcoholic steatohepatitis
AE Feldstein et al.
GASTROENTEROLOGY (2003)
6α-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity
R Pellicciari et al.
JOURNAL OF MEDICINAL CHEMISTRY (2002)
Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis
CJ Sinal et al.
CELL (2000)
Share Paper
